论文部分内容阅读
自1906年英国生理学家Dale首先报导,麦角生物碱可抵销肾上腺素的升压作用,而抑制平滑肌、扩张血管、兴奋心脏的作用毫无影响,并提出肾上腺素的作用至少依赖于两类不同受体。其中一类可被麦角所阻断的这一重要发现,却一直未受到医药界应有的注视。至1948年Ahlquist研究几种拟肾上腺素药物对整个机体、器官的生理作用进行效能比较后,始发现并归纳为两类受体。其中如血管收缩类以去甲肾上腺素最强。另一类肠肌松弛、兴奋心脏则以异两肾上腺素最强。根据这样的药物作用特异件,才提出两类不同的肾上腺素能受体。到了1958年Powell和Slater人工合成α-受体阻滞剂—酚苄明,β受体阻滞剂二氯异丙肾止腺素
Since 1906 British physiologist Dale first reported that ergot alkaloids can counteract the role of epinephrine boost, while inhibiting smooth muscle, dilate blood vessels, the role of excited heart has no effect, and suggested that the role of epinephrine depends on at least two different Receptor. One of the important findings that can be blocked by the ergot has not been what the medical profession should look after. By 1948, Ahlquist studied the effects of several adrenergic drugs on the physiological effects of the entire body and organs, and then discovered and classified them into two types of receptors. Among them, such as vasoconstriction norepinephrine strongest. Another type of relaxation of the intestinal muscle, the excitement of the heart is the strongest two different adrenergic. According to the specific role of such drugs, it was proposed two different types of adrenergic receptors. To 1958 Powell and Slater synthetic α-blocker - phenoxybenzamine, β blockers dichloro isoproterenol